Delayed
Berne S.E.
|
5-day change
|
1st Jan Change
|
- CHF
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
752
|
754
|
651.1
|
577.1
|
40.48
|
14.11
|
-
|
-
|
Enterprise Value (EV)
1 |
752
|
754
|
484.1
|
431.7
|
-60.28
|
35.61
|
93.01
|
-4.994
|
P/E ratio
|
-6.47
x
|
84.1
x
|
-7
x
|
-6.75
x
|
-0.34
x
|
-0.2
x
|
-0.35
x
|
-0.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.8
x
|
5.58
x
|
28.3
x
|
13.8
x
|
1.93
x
|
2.2
x
|
1.91
x
|
1.76
x
|
EV / Revenue
|
37.8
x
|
5.58
x
|
21
x
|
10.3
x
|
-2.87
x
|
5.55
x
|
12.6
x
|
-0.62
x
|
EV / EBITDA
|
-6.75
x
|
135
x
|
-5.45
x
|
-4.95
x
|
0.5
x
|
-0.53
x
|
-1.96
x
|
0.1
x
|
EV / FCF
|
-6.88
x
|
-129
x
|
-8.05
x
|
-5.48
x
|
0.64
x
|
-0.58
x
|
-2.78
x
|
0.18
x
|
FCF Yield
|
-14.5%
|
-0.77%
|
-12.4%
|
-18.2%
|
157%
|
-172%
|
-36%
|
561%
|
Price to Book
|
-
|
-
|
2.86
x
|
3.64
x
|
0.7
x
|
-0.59
x
|
-0.2
x
|
0.74
x
|
Nbr of stocks (in thousands)
|
46,679
|
49,832
|
53,459
|
53,734
|
54,481
|
54,676
|
-
|
-
|
Reference price
2 |
16.11
|
15.13
|
12.18
|
10.74
|
0.7430
|
0.2580
|
0.2580
|
0.2580
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
19.89
|
135.1
|
23.03
|
41.87
|
20.97
|
6.415
|
7.394
|
8.028
|
EBITDA
1 |
-111.5
|
5.594
|
-88.84
|
-87.29
|
-121.2
|
-67.46
|
-47.49
|
-48.72
|
EBIT
1 |
-111.7
|
5.385
|
-89.08
|
-87.54
|
-121.5
|
-70.94
|
-46.77
|
-43.14
|
Operating Margin
|
-561.6%
|
3.99%
|
-386.85%
|
-209.08%
|
-579.43%
|
-1,105.83%
|
-632.47%
|
-537.41%
|
Earnings before Tax (EBT)
1 |
-107.2
|
7.719
|
-88.44
|
-85.47
|
-118.5
|
-72.35
|
-44.32
|
-39.87
|
Net income
1 |
-106.4
|
8.41
|
-88.44
|
-85.47
|
-118.5
|
-72.35
|
-44.32
|
-39.87
|
Net margin
|
-534.91%
|
6.23%
|
-384.06%
|
-204.16%
|
-565.21%
|
-1,127.83%
|
-599.41%
|
-496.61%
|
EPS
2 |
-2.490
|
0.1800
|
-1.740
|
-1.590
|
-2.190
|
-1.260
|
-0.7350
|
-0.4667
|
Free Cash Flow
1 |
-109.2
|
-5.836
|
-60.13
|
-78.77
|
-94.45
|
-61.2
|
-33.5
|
-28
|
FCF margin
|
-549.35%
|
-4.32%
|
-261.1%
|
-188.15%
|
-450.46%
|
-954.04%
|
-453.05%
|
-348.77%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.821
|
4.79
|
23
|
10.81
|
3.261
|
6.165
|
6.933
|
4.866
|
3.004
|
2.135
|
1.174
|
1.75
|
1.378
|
1.2
|
1
|
EBITDA
1 |
-33.46
|
-27.85
|
-4.409
|
-23.78
|
-31.25
|
-27.59
|
-32.28
|
-28.84
|
-32.52
|
-29.62
|
-13.71
|
-12
|
-12.02
|
-
|
-
|
EBIT
1 |
-33.52
|
-27.91
|
-4.472
|
-23.84
|
-31.31
|
-27.65
|
-32.34
|
-28.9
|
-32.61
|
-29.67
|
-14.81
|
-14.02
|
-12.42
|
-16.5
|
-17.6
|
Operating Margin
|
-4,083.07%
|
-582.69%
|
-19.44%
|
-220.52%
|
-960.04%
|
-448.5%
|
-466.46%
|
-593.88%
|
-1,085.45%
|
-1,389.51%
|
-1,261.59%
|
-801.33%
|
-901.76%
|
-1,375%
|
-1,760%
|
Earnings before Tax (EBT)
1 |
-33.38
|
-27.75
|
-4.206
|
-23.18
|
-30.34
|
-26.66
|
-31.48
|
-28.03
|
-32.34
|
-30.7
|
-14.91
|
-14.25
|
-12.49
|
-16.2
|
-17.3
|
Net income
1 |
-33.38
|
-27.75
|
-4.206
|
-23.18
|
-30.34
|
-26.66
|
-31.48
|
-28.03
|
-32.34
|
-30.7
|
-14.91
|
-14.25
|
-12.49
|
-16.2
|
-17.3
|
Net margin
|
-4,066.02%
|
-579.31%
|
-18.28%
|
-214.37%
|
-930.36%
|
-432.52%
|
-454.05%
|
-576.08%
|
-1,076.46%
|
-1,437.75%
|
-1,270.49%
|
-814.34%
|
-906.59%
|
-1,350%
|
-1,730%
|
EPS
2 |
-0.6300
|
-0.5200
|
-0.0800
|
-0.4300
|
-0.5600
|
-0.4900
|
-0.5800
|
-0.5200
|
-0.5900
|
-0.5600
|
-0.2725
|
-0.2325
|
-0.1975
|
-0.2000
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/6/23
|
5/15/23
|
8/7/23
|
11/13/23
|
3/4/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
21.5
|
78.9
|
-
|
Net Cash position
1 |
-
|
-
|
167
|
145
|
101
|
-
|
-
|
19.1
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.3187
x
|
-1.661
x
|
-
|
Free Cash Flow
1 |
-109
|
-5.84
|
-60.1
|
-78.8
|
-94.5
|
-61.2
|
-33.5
|
-28
|
ROE (net income / shareholders' equity)
|
-66.4%
|
3.86%
|
-37.1%
|
-44.3%
|
-110%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-34.1%
|
-39.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
259.1
|
214.6
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
4.250
|
2.950
|
1.050
|
-0.4400
|
-1.300
|
0.3500
|
Cash Flow per Share
2 |
-
|
-0.1200
|
-
|
-1.470
|
-1.700
|
-1.070
|
-0.5600
|
-0.3600
|
Capex
1 |
0.02
|
0.35
|
0.04
|
0.04
|
2.38
|
1.8
|
1.65
|
1.65
|
Capex / Sales
|
0.09%
|
0.26%
|
0.17%
|
0.1%
|
11.33%
|
28.06%
|
22.31%
|
20.55%
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Last Close Price
0.258
USD Average target price
1.65
USD Spread / Average Target +539.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.08% | 95.18B | | -4.34% | 37.55B | | +75.79% | 28.2B | | -14.61% | 15.63B | | -3.46% | 13.63B | | -12.31% | 11.5B | | +184.77% | 10.81B | | -54.13% | 9.23B | | +6.22% | 9.09B |
Biopharmaceuticals
|